CA
NZ
UK
AU
IND
US
…
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Acumen Pharmaceuticals (NASDAQ: ABOS) is a development-stage biotechnology company that, according to public filings, advances therapeutic candidates through preclinical and clinical development. Long-term growth may be driven by clinical and regulatory milestones, licensing or partnership deals, and addressing unmet needs in its target indications, which could support value creation.
Key risks include clinical or regulatory failure, high cash burn with likely need for additional financing, intense competition in biopharma and limited operating history; investors should monitor cash runway and upcoming trial readouts.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -121.33M | -102.33M | -52.37M | -42.86M | -100.61M |
| Net income | -121.33M | -102.33M | -52.37M | -40.48M | -181.68M |
| Selling general administrative | 18.95M | 20.22M | 18.82M | 12.88M | 7.28M |
| Selling and marketing expenses | - | - | 0.18M | - | - |
| Gross profit | -0.18M | -0.18M | -42.32M | - | - |
| Reconciled depreciation | 0.18M | 0.18M | 0.19M | 0.17M | 0.00M |
| Ebit | - | -98.26M | -51.79M | -45.24M | 61.57M |
| Ebitda | -123.83M | -98.08M | -51.61M | -45.07M | 61.58M |
| Depreciation and amortization | - | 0.18M | 0.18M | 0.17M | 0.00M |
| Non operating income net other | - | - | - | -0.01M | -81.11M |
| Operating income | -123.83M | -114.02M | -61.14M | -45.24M | 61.57M |
| Other operating expenses | 123.83M | 114.02M | 61.14M | 45.24M | 19.58M |
| Interest expense | 4.22M | 4.07M | 0.58M | 2.38M | 81.02M |
| Interest income | 7.45M | 14.32M | 8.23M | 2.39M | 0.08M |
| Net interest income | 3.22M | 10.25M | 8.23M | 2.39M | 0.08M |
| Income tax expense | - | - | - | -2.38M | 81.07M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 123.83M | 114.02M | 61.14M | 45.24M | 19.58M |
| Cost of revenue | 0.18M | 0.18M | 42.32M | - | - |
| Total other income expense net | 2.50M | 11.69M | 8.77M | 2.38M | -162.18M |
| Net income from continuing ops | -121.33M | -102.33M | -48.74M | -42.86M | -100.61M |
| Net income applicable to common shares | - | - | - | -42.86M | -100.61M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 122.83M | 238.99M | 310.12M | 196.59M | 230.33M |
| Intangible assets | 0.03M | 0.07M | - | - | - |
| Other current assets | 4.76M | 6.59M | 2.87M | 2.72M | 4.42M |
| Total liab | 52.40M | 57.18M | 43.15M | 7.81M | 5.15M |
| Total stockholder equity | 70.43M | 181.82M | 266.97M | 188.78M | 225.18M |
| Other current liab | 20.54M | 21.83M | 10.73M | 6.07M | 4.06M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M |
| Retained earnings | -446.46M | -325.13M | -222.80M | -170.43M | -127.57M |
| Other assets | - | - | 0.00M | 0.15M | 0.01M |
| Cash | 53.99M | 35.63M | 66.89M | 130.10M | 122.16M |
| Total current liabilities | 30.01M | 27.61M | 12.97M | 7.81M | 5.15M |
| Net debt | -22.68M | -5.92M | -35.84M | -130.00M | -122.16M |
| Short term debt | 8.91M | 0.13M | 0.87M | 0.10M | 0.14M |
| Short long term debt | 8.77M | - | - | - | - |
| Short long term debt total | 31.31M | 29.70M | 31.05M | 0.10M | 0.20M |
| Other stockholder equity | 516.80M | 506.99M | 489.45M | 359.95M | 122.65M |
| Property plant equipment | - | - | - | 0.17M | 0.04M |
| Total current assets | 122.25M | 178.31M | 246.62M | 180.33M | 198.66M |
| Long term investments | 0.00M | 59.97M | 62.55M | 15.84M | 31.62M |
| Net tangible assets | - | - | - | 188.78M | 225.18M |
| Short term investments | 62.88M | 135.93M | 176.64M | 47.50M | 72.08M |
| Net receivables | 0.62M | 0.40M | 0.23M | 0.10M | 0.10M |
| Long term debt | 22.40M | 28.45M | 27.34M | - | - |
| Inventory | - | 0.16M | 0.00M | 0.20M | 0.08M |
| Accounts payable | 0.55M | 5.65M | 1.38M | 1.64M | 1.09M |
| Accumulated other comprehensive income | 0.08M | -0.05M | 0.31M | -0.75M | -0.23M |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Retained earnings total equity | - | - | - | -170.43M | -127.57M |
| Non currrent assets other | 0.58M | 0.38M | 0.22M | 0.15M | 0.01M |
| Non current assets total | 0.58M | 60.69M | 63.51M | 16.26M | 31.67M |
| Capital lease obligations | 0.15M | 0.28M | 1.15M | 0.10M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 134.02M | 48.03M | -143.28M | 39.35M | -104.08M |
| Change to liabilities | - | - | - | 2.56M | 0.56M |
| Total cashflows from investing activities | 133.93M | 48.03M | -171.67M | 39.19M | -104.12M |
| Net borrowings | 0.00M | -0.74M | 30.00M | - | - |
| Total cash from financing activities | -0.03M | 6.93M | 151.75M | 3.91M | 200.47M |
| Change to operating activities | - | - | - | 3.43M | -0.26M |
| Net income | -121.33M | -102.33M | -52.37M | -42.86M | -100.61M |
| Change in cash | 18.36M | -31.26M | -62.98M | 7.94M | 78.39M |
| Begin period cash flow | 35.86M | 67.12M | 130.10M | 122.16M | 43.78M |
| End period cash flow | 54.22M | 35.86M | 67.12M | 130.10M | 122.16M |
| Total cash from operating activities | -115.54M | -86.22M | -43.06M | -35.15M | -17.96M |
| Issuance of capital stock | 0.00M | 7.94M | 126.09M | 3.79M | 198.59M |
| Depreciation | -0.75M | 0.18M | 0.18M | 0.17M | 0.00M |
| Other cashflows from investing activities | - | - | 0.00M | - | - |
| Dividends paid | - | 0.00M | 0.00M | - | - |
| Sale purchase of stock | -0.07M | -0.04M | 0.00M | 3.91M | 170.44M |
| Other cashflows from financing activities | - | -0.23M | -0.15M | 0.12M | 31.91M |
| Change to netincome | - | - | - | 3.06M | 82.34M |
| Capital expenditures | 0.09M | 0.02M | 0.02M | 0.16M | 0.04M |
| Cash flows other operating | - | - | - | 1.56M | 77.26M |
| Cash and cash equivalents changes | - | - | - | 7.94M | 78.39M |
| Change in working capital | -5.12M | 11.65M | 3.87M | 3.99M | 0.30M |
| Stock based compensation | 9.85M | 9.63M | 6.14M | 3.06M | 0.92M |
| Other non cash items | 1.81M | -5.35M | -0.89M | 0.49M | 81.27M |
| Free cash flow | -115.63M | -86.23M | -43.09M | -35.31M | -18.00M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABOS Acumen Pharmaceuticals Inc |
-2.08 90.83% |
0.21 | - | - | 538.78 | 3.52 | 24.48 | -0.60 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel J. O'Connell M.B.A. | CEO, Pres & Director | 1971 |
| Mr. Matt Zuga | CFO, Chief Bus. Officer & Corp. Sec. | NA |
| Dr. Eric Siemers M.D. | Chief Medical Officer | 1955 |
| Mr. Russell Barton M.S. | Chief Operating Officer | 1959 |
| Mr. Derek M. Meisner Esq., J.D. | Chief Legal Officer | 1971 |
| Ms. Robyn Moxon M.A. | Mang. of Corp. & Clinical Communications | NA |
| Ms. Julie Bockenstette | Exec. VP & Head of HR | NA |
| Ms. Siew Tin Gan M.S. | Assistant VP & Head of Clinical Operations | NA |
| Ms. Janice Hitchcock | VP & Head of Regulatory Affairs | NA |
| Ms. Liean Schenck M.S. | VP & Head of CMC | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...